Literature DB >> 18510891

Effects of antiretroviral therapy on cognitive impairment.

Kevin J Liner1, Colin D Hall, Kevin R Robertson.   

Abstract

Since the introduction of combination antiretroviral therapy, the manifestations of HIV-associated central nervous system (CNS) involvement have generally become less severe and more manageable. Patients initiating antiretroviral therapy have demonstrated improvement in cognitive functioning. Reduction of viral burden has been correlated with improved CNS functioning. Recent studies have focused on the importance of CNS-penetrating antiretroviral regimens to target active replication in this protected compartment. There were initial conflicting reports of whether CNS-penetrating antiretrovirals improved cognitive functioning, with more evidence supporting the importance of CNS penetration in reducing viral burden and improving cognitive outcomes. Cognitive loss remains a feature of HIV infection, and some patients still suffer from incident or progressing cognitive and motor dysfunction even on combination therapy. Because the virus enters the CNS within days of initial infection, latent infection may be chipping away at the brain during the long asymptomatic period in HIV. When to start antiretrovirals for the maximum cognitive benefit remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510891     DOI: 10.1007/s11904-008-0011-7

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  56 in total

1.  HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.

Authors:  Jutta K Neuenburg; Hans R Brodt; Brian G Herndier; Markus Bickel; Peter Bacchetti; Richard W Price; Robert M Grant; Wolfgang Schlote
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

2.  Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.

Authors:  Gregory J Dore; Ann McDonald; Yueming Li; John M Kaldor; Bruce J Brew
Journal:  AIDS       Date:  2003-07-04       Impact factor: 4.177

3.  Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

Authors:  Alain Lafeuillade; Caroline Solas; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  HIV Clin Trials       Date:  2002 Jan-Feb

4.  Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy.

Authors:  C G Filippi; G Sze; S J Farber; M Shahmanesh; P A Selwyn
Journal:  Radiology       Date:  1998-02       Impact factor: 11.105

5.  Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.

Authors:  N Sacktor; N Nakasujja; R Skolasky; K Robertson; M Wong; S Musisi; A Ronald; E Katabira
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

6.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Two phases of HIV RNA decay in CSF during initial days of multidrug therapy.

Authors:  D W Haas; B W Johnson; P Spearman; S Raffanti; J Nicotera; D Schmidt; T Hulgan; R Shepard; S A Fiscus
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

8.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

9.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

10.  Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS.

Authors:  K C Williams; S Corey; S V Westmoreland; D Pauley; H Knight; C deBakker; X Alvarez; A A Lackner
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  23 in total

1.  Treatment regimens for HIV neurocognitive dysfunctions in the highly active antiretroviral therapy (HAART) era.

Authors:  Burk Jubelt
Journal:  Curr Neurol Neurosci Rep       Date:  2010-11       Impact factor: 5.081

2.  Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Authors:  Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah L Puls; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Journal:  Neuroradiology       Date:  2012-07-07       Impact factor: 2.804

3.  [Neurological complications of HIV infection].

Authors:  G Arendt; T Nolting
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

4.  SIV Infection Impairs the Central Nervous System in Chinese Rhesus Macaques.

Authors:  Hang Liu; Qian-Hao Xiao; Jin-Biao Liu; Jie-Liang Li; Li Zhou; Qiao-Yang Xian; Yong Wang; Jing Zhang; Xu Wang; Wen-Zhe Ho; Ke Zhuang
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-06       Impact factor: 4.147

5.  Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.

Authors:  K R Robertson; Z Su; D M Margolis; A Krambrink; D V Havlir; S Evans; D J Skiest
Journal:  Neurology       Date:  2010-03-17       Impact factor: 9.910

Review 6.  Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection.

Authors:  Gabriel Gras; Marcus Kaul
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

7.  Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.

Authors:  Cecile D Lahiri; Kedria Reed-Walker; Anandi N Sheth; Edward P Acosta; Aswani Vunnava; Ighovwerha Ofotokun
Journal:  J Clin Pharmacol       Date:  2015-10-20       Impact factor: 3.126

8.  Emergence of CD4 independence envelopes and astrocyte infection in R5 simian-human immunodeficiency virus model of encephalitis.

Authors:  Ke Zhuang; Ana Rachel Leda; Lily Tsai; Heather Knight; Carole Harbison; Agegnehu Gettie; James Blanchard; Susan Westmoreland; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

9.  Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program.

Authors: 
Journal:  Clin Infect Dis       Date:  2012-11-21       Impact factor: 9.079

10.  Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Authors:  Cecile A Delille; Sarah T Pruett; Vincent C Marconi; Jeffrey L Lennox; Wendy S Armstrong; Richard F Arrendale; Anandi N Sheth; Kirk A Easley; Edward P Acosta; Aswani Vunnava; Ighovwerha Ofotokun
Journal:  J Clin Pharmacol       Date:  2014-04-08       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.